GuidelineDiseases of the esophagus : official journal of the International Society for Diseases of the Esophagus2016
Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals.
Guideline in Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sarcopenia reduces overall survival in unresectable oesophageal cancer: a systematic review and meta-analysis.Journal of cachexia, sarcopenia and muscle · 2022Pooled it
- Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinical trial.Cancer communications (London, England) · 2024Trial
- Is it necessary for patients with potentially resectable esophageal squamous cell cancer to receive routine preoperative brain MRI/CT?Thoracic cancer · 2022Trial
- Article
- Intraoperative recurrent laryngeal nerve monitoring in esophagectomy with lymphadenectomy.Journal of thoracic disease · 2026Article
- Identification of Prognostic Factors in Esophageal Cancer Using Machine Learning: A Retrospective Study Based on the SEER Database.Journal of clinical medicine · 2026Article
- Survival Outcomes of Adjuvant Nivolumab after Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2026Article
- Survival benefit and dynamics of CD8Frontiers in immunology · 2026Article
- A combined tumor burden-based nomogram for synchronous esophageal and gastric cancers: development and external validation.Frontiers in oncology · 2026Article
- Validation and refinement of the 8th edition of the AJCC staging system for esophageal squamous cell carcinoma treated with definitive IMRT or chemo-IMRT: a Chinese multi-institutional retrospective study.Radiation oncology (London, England) · 2025Article
- Diagnostic and therapeutic appropriateness in different stages of esophageal/GEJ cancers. The FICOG project.Future oncology (London, England) · 2025Article
- Impact of endoscopic ultrasonography with fine needle aspiration assessing clinical lymph node staging on radiotherapy treatment planning in esophageal cancer patients.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2025Article
- A comparison of the survival outcome of paclitaxel liposome-based chemoradiotherapy with or without rhEndostatin for unresectable esophageal squamous cell carcinoma: a retrospective study.Discover oncology · 2025Article
- Neoadjuvant chemoimmunotherapy for esophageal squamous cell carcinoma with non-regional cervical lymph node metastasis: a retrospective pilot study.Frontiers in immunology · 2025Article
- Malignant epithelia cells-derived spermine induces APOE+ macrophages to suppress tumor immunity in adenocarcinoma of the esophagogastric junction.Frontiers in medicine · 2025Article
- Case report: Chemotherapy plus sintilimab for the treatment of gastroesophageal junction hepatoid adenocarcinoma with liver metastasis: a case study with literature review.Frontiers in immunology · 2025Review
- Analysis of the short-term efficacy of 2 versus 3 cycles of neoadjuvant immunotherapy combined with chemotherapy in patients with esophageal squamous cell carcinoma.Journal of Cancer · 2025Article
- Role of high-resolution magnetic resonance imaging in preoperative tumor-node-metastasis staging evaluation of esophageal cancer: a narrative review.Quantitative imaging in medicine and surgery · 2024Review
- CT-based delta-radiomics for predicting pathological response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma: a multicenter study.BMC medical imaging · 2024Article
- Adjuvant Therapy after Esophagectomy for Esophageal Cancer: Who Needs It?: Multi-institution Worldwide Observational Study.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2024Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
We report analytic and consensus processes that produced recommendations for clinical stage groups (cTNM) of esophageal and esophagogastric junction cancer for the AJCC/UICC cancer staging manuals, 8th edition. The Worldwide Esophageal Cancer Collaboration (WECC) provided data on 22,123 clinically staged patients with epithelial esophageal cancers. Risk-adjusted survival for each patient was developed using random survival forest analysis from which (1) data-driven clinical stage groups were identified wherein survival decreased monotonically and was distinctive between and homogeneous within groups and (2) data-driven anatomic clinical stage groups based only on cTNM. The AJCC Upper GI Task Force, by smoothing, simplifying, expanding, and assessing clinical applicability, produced (3) consensus clinical stage groups. Compared with pTNM, cTNM survival was "pinched," with poorer survival for early cStage groups and better survival for advanced ones. Histologic grade was distinctive for data-driven grouping of cT2N0M0 squamous cell carcinoma (SCC) and cT1-2N0M0 adenocarcinoma, but consensus removed it. Grouping was different by histopathologic cell type. For SCC, cN0-1 was distinctive for cT3 but not cT1-2, and consensus removed cT4 subclassification and added subgroups 0, IVA, and IVB. For adenocarcinoma, N0-1 was distinctive for cT1-2 but not cT3-4a, cStage II subgrouping was necessary (T1N1M0 [IIA] and T2N0M0 [IIB]), advanced cancers cT3-4aN0-1M0 plus cT2N1M0 comprised cStage III, and consensus added subgroups 0, IVA, and IVB. Treatment decisions require accurate cStage, which differs from pStage. Understaging and overstaging are problematic, and additional factors, such as grade, may facilitate treatment decisions and prognostication until clinical staging techniques are uniformly applied and improved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.